Általános Orvostudományi Kar
Das Pradhan, A., Glynn, R., Fruchart, J., MacFadyen, J., Zaharris, E., Everett, B., Campbell, S., Oshima, R., Amarenco, P., Blom, D., Brinton, E., Eckel, R., Elam, M., Felicio, J., Ginsberg, H., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., … Prominent Investigators. (2022). Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
NEW ENGLAND JOURNAL OF MEDICINE,
387(21), 1923–1934.
https://doi.org/10.1056/NEJMoa2210645Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., Acevedo, A., Sukhin, V., Cloven, N., Gomes, A., Mejia, F., Reiss, A., Ayhan, A., Lee, J., Saevets, V., Zagouri, F., Gilbert, L., Sehouli, J., Tharavichitkul, E., … ENGOT-cx11-GOG-3047 KEYN. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial.
LANCET,
403(10434), 1341–1350.
https://doi.org/10.1016/S0140-6736(24)00317-9Tran, K., Lang, J., Compton, K., Xu, R., Acheson, A., Henrikson, H., Kocarnik, J., Penberthy, L., Aali, A., Abbas, Q., Abbasi, B., Abbasi-Kangevari, M., Abbasi-Kangevari, Z., Abbastabar, H., Abdelmasseh, M., Abd-Elsalam, S., Abdelwahab, A., Abdoli, G., Abdulkadir, H., … Murray, C. (2022). The global burden of cancer attributable to risk factors, 2010-19: A systematic analysis for the Global Burden of Disease Study 2019.
LANCET,
400(10352), 563–591.
https://doi.org/10.1016/S0140-6736(22)01438-6
